| 证券代码 | TRPX.O |
| 证券名称 | Therapix Biosciences Ltd ADR |
| 证券类型 | 美国存托凭证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-03-22 |
| 首发价格(元) | 6 USD |
| 首发数量(股) | 2000000 |
| 首发募资额(元) | 12,000,000.00 USD |
| 首发主承销商 | Laidlaw & Company (UK) Ltd. |
| 货币单位 | USD |
| 公司名称 | SciSparc Ltd. |
| 注册地址 | 以色列 |
| 办公地址 | 20 Raul Wallenberg St., Tower A, 2nd Floor, Tel Aviv, Israel |
| 成立日期 | 2004-08-23 |
| 董事会主席 | Amity Weiss |
| 公司属地 | Israel 以色列 |
| 公司网址 | www.scisparc.com |
| 电话 | +972 (3) 610-3100 |
| 传真 | - |
| 公司简介 | SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (“SciSparc” or the “Company”), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time (the “Group”) were mainly engaged in developing several innovative immunotherapy products and SciSparc’s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in the following development programs based on Δ9-tetrahydrocannabinol (“THC”) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea, pain, Autism Spectrum Disorder and epilepsy. The headquarters of the Company are located in the Tel Aviv, Israel. |